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Background
The introduction of next-generation DNA sequencing
devices into the field of oncology provides an unprece-
dented mechanism to determine the underlying genetic
changes that have occurred within a tumor and also the
changes that accrue during treatment. An enhanced
understanding of the oncogenic mechanisms could have
an immediate clinical role in the treatment of rare
tumors - where treatment protocols do not exist and
their rarity would indicate that clinical trials would be
unlikely to be undertaken for their establishment.
Results
We have investigated the utility of massively parallel
sequencing to characterize a rare adenocarcinoma of the
tongue, before and after treatment. In the pre-treatment
tumor we identified 7,629 genes within regions of copy
number gain, 1,078 genes exhibited increased expression
relative to the blood and unrelated tumors and four
genes contained somatic protein-coding mutations. Our
analysis suggested the tumor cells were driven by the
RET oncogene and its other pathway constituents. Genes
whose protein products are targeted by the RET inhibi-
tors sunitinib and sorafenib correlated with being ampli-
fied and or highly expressed. Consistent with our
observations subsequent administration of sunitinib was
associated with stable disease lasting 4 months, after
which the lung lesions began to grow. Administration of
sorafenib and sulindac provided disease stabilization for
an additional 3 months after which the cancer progressed
and new lesions appeared. A metastasis recurring in the
skin was determined to possess 7,288 genes within copy
number amplicons, 385 genes exhibiting increased
expression relative to other tumours and 9 new somatic
protein coding mutations. The observed mutations and
amplifications were found to be consistent with resis-
tance to therapy arising through further activation of
RET pathway and nascent activation of the AKT
pathway.
Conclusion
Our results provide evidence for the clinical utility of
complete genomic characterization and direct in-vivo
genome-wide characterization of the mutations accruing
within a tumor under drug selection.
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